Cardiovascular Toxicity And Therapeutic Modalities Targeting Cardio Oncology

Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. Anti-cancer treatment is associated with serious cardiovascular adverse events, including arterial and pulmonary hypertension, supraventricular and ventricular arrhythmias, systolic and diastolic cardiac dysfunction and coronary artery disease. Progress in cancer therapy over the past decades improved long-term survival but increased cancer therapy-related cardiotoxicity. Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death. Adopts a translational approach and comprehensively covers the basic science, mechanisms and concepts of cardio-oncology Outlines the current knowledge of biomarkers in cancer therapy-related cardiotoxicity Provides an understanding of the mechanisms of cardiovascular toxicity of various therapies that may lead to the identification of novel targets to reduce vascular complications

Cardio-Oncology: Principles, Prevention and Management is a clinical volume that focuses on the basic science of cardio-oncology, addresses cardiotoxicity as a consequence of cancer therapy, and discusses prevention, diagnosis and management of cardiovascular disease in patients with cancer. This comprehensive volume presents unique perspectives ranging from basic science to clinical medicine in the field of cardio-oncology. It would be a valuable resource for cardiologists, oncologists, internists, and pediatricians caring for patients with cancer who have cardiovascular risk factors, as well as for cardio-oncology researchers. Covers basic science of cardio-oncology to provide readers with the necessary background Addresses cardiotoxicity related to current cancer therapeutic modalities Discusses diagnostic and management approaches of patients with underlying cardiac risk factors as well as otherwise healthy cancer patients

This book takes a holistic view of the treatment of cardio-oncology patients, from evaluating those at high risk of developing cardio-toxicity, guidance for monitoring and managing patients during therapy to cardiac care of cancer survivors. Throughout, this book utilizes the latest research and guidance to offer advice on treatment strategy as well as practical elements of such as training, cardio-oncology nursing, patient education and how to establish a cardio-oncology unit. This book focuses on the practical knowledge and skills key to successful collaboration between cardiologists and oncologists to achieve the optimum cardiac care for cancer patients. Key Features Focuses on the practical elements of cardio-oncology care Outlines the importance and process of setting up a cardio-oncology unit and cardio-oncology fellowships Provides advice and guidance on the set up and common pit falls of coordinating care for cardio-oncology patients Outlines current guidelines and potential future directions for the field of cardio-oncology

This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing, during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects. The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.

Over the last years, thanks to growing advances in the field of cancer therapies, a considerable decrease in cancer mortality has been observed. Unfortunately, such therapies have shown a wide spectrum of cardiotoxicities. This book provides the readers with the latest advances and insights in the ever-expanding field of Cardio-Oncology. Specific topics discussed in the book include the potential role of inflammation in Cardio-Oncology and the description of the different manifestations of cardiotoxicities (including vascular toxicity, systemic hypertension, arrhythmias), analyzing the complex relationships between cancer and heart failure, two conditions whose prevalence increases with ageing. Furthermore, the role of biomarkers and imaging in cardio-oncology is discussed.

Co-edited and written by an interdisciplinary team of experts in oncology and cardiology, this book is a clinically useful resource on these overlapping topics: • Cardiac complications in patients receiving cancer therapy • The treatment of cancer in patients with cardiovascular disease • The treatment of cardiovascular disease in patients with cancer When relevant to medical practice, epidemiology and basic science are also included in the discussion and each chapter is written by an oncologist and a cardiologist. Additionally, the chapters follow a similar format to make the book truly interdisciplinary, user-friendly, and clinically applicable to specialists and non-specialists who care for patients with both cancer and cardiovascular disease.

In this issue of Heart Failure Clinics, guest editors Drs. Ragavendra R Baliga and George A. Mensah bring their considerable expertise to the topic of Translational Research in Cardio-Oncology. Top experts in the field cover key topics such as radiation-induced cardiac dysfunction; training and career development; cardiovascular imaging; CAR-T cell therapy and cardiovascular disease; and more. Contains 12 relevant, practice-oriented topics including cardio-protection of high-risk individuals; myocardial metabolism; amyloidosis; arrhythmic complications associated with cancer therapies; and more. Provides in-depth clinical reviews on translational research in cardio-oncology, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Today’s patients have unique cardiologic needs before, during, and after cancer treatment. Chemotherapies, radiation therapy, and targeted therapies can produce acute side effects or lasting adverse consequences on the heart and circulatory system, making the field of cardio-oncology increasingly important in effective patient care. Cardio-Oncology Practice Manual is a comprehensive, portable guide that provides practical approaches to assessment and management of cardiovascular diseases due to the effects of cardiotoxic agents and treatments. Part of the Braunwald family of renowned cardiology references, it clearly presents clinically relevant aspects of this growing field in one quick, practical reference for a wide range of cardio-oncology providers. Covers all major cancer therapies, cardiovascular toxicities, and malignancies in a portable, authoritative guide—ideal for cardiologists, cardio-oncologists, general practitioners, internists, medical oncologists, and hematologists. Offers templated and streamlined content for quick retrieval, with key point summaries for each major section. Presents cardiac disease entities and specific malignant diseases in a succinct overview format addressing important clinical care aspects. Features "Central Illustrations" for each topic that visually summarize the chapter and its specific content including algorithms for management of cardiovascular toxicities and one-view overviews of malignancies. Includes a comprehensive drug guide that provides quick reference to drugs prescribed for cancers with therapeutic indications, manifestations and mechanisms of cardiotoxicity, their risk factors, and risk reduction strategies. Brings you up to date with new immune therapies, including immune checkpoint inhibitors and CAR T-cell therapies